Friday, December 18, 2009

Daily Business Update from the Boston Globe

To ensure you receive your Boston.com e-mails, please add newsletters@boston.com to your address book.

If you have trouble reading this e-mail, go to http://www.boston.com/business/ticker_headlines


Get up-to-the-minute Globe Business Updates   |  More Business News
 
ADVERTISEMENT

Friday, December 18, 2009

Marblehead lawyer charged in mortgage scheme
. By Jenifer B. McKim, Globe Staff Marblehead lawyer Leon Gelfgatt is scheduled to be arraigned today in Cambridge District Court in Medford in connection with an alleged million-dollar mortgage hijacking scheme. Gelfgatt was arrested yesterday by State Police...

Boston wins tax fight against National Grid
By Casey Ross, Globe Staff Boston tax officials have won a seven-year tax fight against National Grid after a state panel rejected the utility's claim that it was owed about $16 million in refunds because the city had overvalued its...

Cisco closes $2.9 billion deal for Starent
The Associated PressNEW YORK -- Cisco Systems Inc. said Friday it has completed its $2.9 billion acquisition of Starent Networks Corp.Cisco, the world's largest maker of computer networking gear, paid $35 per share in cash, for Starent, a company based...

Today in Globe Business
New CEO inheriting heavy load at bank With his new job as head of the nation?s largest bank, Brian Moynihan would seem to have the weight of the US economy on his shoulders. Tapped Wednesday to be the next chief...

Thursday, December 17, 2009

Extended unemployment checks are on the way
By Robert Gavin, Globe Staff More than 26,000 Massachusetts residents who qualified for the recently approved extension of federal unemployment benefits will soon receive their first checks, state labor officials said. The checks, totalling nearly $41 million, were mailed this...

Aveo expects to raise $86.3 million in IPO
Associated Press Aveo Pharmaceuticals Inc. said Wednesday it plans on raising about $86.3 million in an initial public stock offering. The Cambridge biotech company has not yet disclosed how many shares it plans on offering or set a pricing range....

No comments:

Post a Comment